Close Menu

NEW YORK (GenomeWeb) – Cancer Genetics announced today that it plans to sell its wholly owned subsidiary, BioServe Biotechnologies, to Reprocell for up to $1.9 million.

Under the terms of the acquisition, Reprocell , a Japanese stem cell research company, will pay Cancer Genetics $1.6 million upfront. The remaining balance will be payable about six months after the deal's closing, subject to BioServe's revenues for a four-month period after closing being equivalent to the same four-month period in 2017.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.